Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: a modelling approach

Lung cancer is a major global health issue [1]. According to the GLOBOCAN 2020 database, the incidence of lung cancer was 2.207 million, accounting for 11.4% of all cancer cases. The number of deaths owing to lung cancer was 1.796 million, taking up 18.0% of all deaths. Compared with female breast cancer, lung cancer is the most widespread and is the leading cause of death due to cancer in males, with an estimated 1.436 million new cases and 1.189 million deaths in 2020 [2]. In the two broad histologic subtypes of lung cancer, non-small cell lung cancer (NSCLC) constitutes approximately 85–90% [3]. Furthermore, 60–70% of patients with lung cancer are often diagnosed at stages III and IV where an overall 5-year survival rate is dismal [4‐6]. Therefore, improving survival and quality of life for patients with advanced NSCLC is of utmost relevance.

In the past decades, immunotherapies have led to prolong overall survival (OS) and progression-free survival (PFS). Recent studies showed that first-line immunotherapy combinations regimen, including immune checkpoint inhibitors (ICI) plus chemotherapy, ICI with anti-angiogenesis drugs, and ICI combinations achieve better clinical efficacy compared with that obtained with chemotherapy in KEYNOTE-189 trial, IMpower150 trial, and CheckMate 9LA trial [7‐9]. However, in the phase 3 MYSTIC trial, immunotherapy combinations did not improve OS compared with that of chemotherapy alone [10]. Because of the uncertainty of results, a series of meta-analyses were conducted in recent years [11‐15]. Among them, several studies were also performed to further demonstrate the clinical benefit of currently available first-line immunotherapy combination in the treatment of patients with advanced NSCLC [16‐18]. They demonstrated that immunotherapy combinations lead to higher efficacy, and improve clinical practice to some extent.

However, only considering clinical efficacy and safety could not meet the demand of real decision-making practice. Economic burden are also the important factors for decision makers. Compared with chemotherapy, the economic burden of immunotherapy combination is dramatically increasing from the perspective of payers including national health care insurance payers, commercial payers, and patients. Although previous studies have evaluated the cost-effectiveness of several immunotherapy regimens [19, 20], an optimal cost-effective immune agent has not yet been elucidated owing to the limited number of immune drugs involved in each study. To facilitate health care decision, a comprehensive comparison of the cost-effectiveness of all immunotherapy combinations is necessary.

Thus, through this study, we aimed at exploring the cost-effectiveness of first-line immunotherapy combinations in the treatment of advanced NSCLC from the perspective of the Chinese health care system, in order to facilitate clinical practice and policy making, thereby creating a reference for developing countries.

This cost-effectiveness analysis was conducted according to the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement, which was the guidance for health economic evaluation [21].

To our knowledge, our study is the first comprehensive economic evaluation for the main immunotherapy combinations. In the methodology, common patients from one trial (IMpower130) were explored to infer to other immunotherapy trials in order to adjust for the confounding factors. The ICERs of ten immunotherapy combinations compared with chemotherapy alone were from $34,912.09/QALY to $777,493.08/QALY. This finding serves as a basis for other developing countries (with per capital GDP and per capital health expenditure similar to that of China) to choose a reasonable and affordable price for health care system or payers.

Previous economic evaluation for head-to-head comparison of immunotherapy combination have shown that nivolumab plus ipilimumab was a cost-effective option in the United States, but not the preferred option in China [49, 50]. Moreover, pembrolizumab plus platinum and pemetrexed as the first-line treatment was not cost-effective in China [51]. Atezolizumab combination therapy was not cost-effective in the United States and China [52‐54]. Our study revealed similar findings, and assessed more immune combination regimens.

The differences of ICER stemmed from the following reasons. First, transition probabilities in PFS, PD, and death were one of the main impact factors of ICER. HR was used to construct the PFS and OS curves of immunotherapy combinations and chemotherapy in this study. Thus, different HRs led a significant difference in the transition probability. For example, regarding OS, the HR of immunotherapy combination versus chemotherapy was from 0.59 to 0.94. Regarding PFS, this value was from 0.45 to 1.25 [22]. Second, the result of DSA showed that the utility of health state and the price of immunotherapy also contributed to these differences. The PFS and PD utility values were both obtained from a study conducted by Nafees. More comparisons and choices were limited due to the lack of evidence on the utility in the Chinese population. For the immunotherapy price, camrelizumab, toripalimab, and tislelizumab entered the national basic medical care insurance catalogue in China through price cut [31]. Although the price kept original such as pembrolizumab and nivolumab, new market strategies were conducted to be faced with the challenge from other PD-1 inhibitors. For example, the patient assistance program (PAP) of pembrolizumab was implemented: Patients who bought the first two cycles got the next two cycles for free, and then purchased the fifth and sixth cycles, the other cycles for two years were also free. The results of probabilistic sensitivity analysis also indicated that the cost-effectiveness probability for pem-chemo was 32.01% after the price of pembrolizumab dropped by 90%. Third, when PD-1/PD-L1 inhibitors combined with ipilimumab or bevacizumab, it increased the economic burden of patients.

The first PD-1 inhibitor-pembrolizumab was approved by US FDA in the year 2014. Accumulating evidence on immunotherapy from long-term follow-up studies and real-world data will render the HR more stable, thereby yielding more valid and reliable evidence on economic evaluation in the future. Meanwhile, there are controversies and various suggestions for the treatment of patients with NSCLC such as subsequent therapy for first-line receiving immunotherapy [34, 55]. The progress in these clinical areas will support specific and optimal choice for drug regimen set in the model. More importantly, the price strategy for acceptable ICER need both multinational pharmaceutical enterprises and Chinese local enterprises to maintain the balance between global pricing strategies and gaining more market share, single pricing strategy and various pricing strategies, the reimbursement of R&D cost and the affordability of patients, especially in the context of the global downward pressure on the economy.

This study has a few limitations. First, the treatment effect of durva-treme-chemo and atezo-beva-chemo respectively compared with chemotherapy alone only have indirect comparison in the network meta-analysis [22]. Although indirect comparison provide useful statistical technique to estimate treatment effect when direct comparisons are absent, they are low in power, with indeterminate results, and significant uncertainty [56‐59]. The uncertainty of survival analysis might bring the uncertainty of economic evaluation in our study; therefore, head-to-head trial for durva-treme-chemo and atezo-beva-chemo respectively compared with chemotherapy alone would be warranted. Second, owing to lack of the network meta-analysis of each adverse event incidence [22], the weighted method was used in this study, thereby possibly increasing deviations compared with the synthetic evidence. Third, in the real-world, clinical treatments are complex and diverse. However, a unified drug regimen was set in order to highlight the differences among the immunotherapies. Fourth, the model in this study was based on a series of assumptions such as proportional hazard, which limited the extrapolation of the result.

In the present study, we assessed the cost effectiveness of immunotherapy combinations versus chemotherapy alone in China. Among the immunotherapy combinations, sintilimab plus chemotherapy provided the best QALY benefit versus chemotherapy, and also appeared a better economic outcome. Although atezolizumab plus bevacizumab plus chemotherapy also provided favorable QALY, the economic outcome was unlikely to be ideal. Our findings revealed that much lower progression and death risk, and a competitive price for immunotherapy combination led to an acceptable ICER for Chinese patients with NSCLC. This serves as an evidence for pharmaceutical enterprises to properly and deeply consider the pricing strategy based on effectiveness and safety in the real-world condition.